Table 2.
Comparison of KRAS status in tumor tissue and pre-surgery plasma in 242 patients with available paired samples*
| Tumor tissue | |||||
|---|---|---|---|---|---|
| Plasma | Direct sequencing | ||||
| Wild type | Mutated | Total | Kappa | p value † | |
| Direct sequencing | |||||
| Wild-type (%) | 138 (57) | 63 (26) | 201 | ·278 | <0 · 001 |
| Mutated (%) | 11 (5) | 30 (12) | 41 | ||
| Total | 149 | 93 | 242 | ||
| PNA-PCR | PNA-PCR | ||||
| Wild-Type (%) | 113 (47) | 53 (22) | 166 | ·456 | <0 · 001 |
| Mutated (%) | 12 (5) | 64 (26) | 76 | ||
| Total | 125 | 117 | 242 | ||
*Kappa test was used to estimate the concordance of KRAS status between tumor tissue and plasma samples.
†All Wald statistical tests were two-sided.
PNA-PCR, peptide-nucleic-acid-mediated polymerase chain reaction clamping.